blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1765378

EP1765378 - AGENT CAPABLE OF DOWNREGULATING AN MSF-A-DEPENDENT HIF-1A AND USE THEREOF IN CANCER TREATMENT [Right-click to bookmark this link]
Former [2007/13]AGENT CAPABLE OF DOWNREGULATING AN MSF-A-DEPENDENT HIF-1A ANDUSE THEREOF IN CANCER TREATMENT
[2013/10]
StatusNo opposition filed within time limit
Status updated on  20.02.2015
Database last updated on 11.05.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Medical Research Fund of Tel Aviv Sourasky Medical Center
6 Weizmann Street
64 239 Tel Aviv / IL
[2014/16]
Former [2007/13]For all designated states
Medical Research Fund of Tel Aviv Sourasky Medical Center
6 Weizmann Street
64 239 Tel Aviv / IL
Inventor(s)01 / MABJEESH, Nicola, J.
28 Rembrandt Street
64045 Tel-Aviv / IL
 [2007/13]
Representative(s)Dennemeyer & Associates S.A.
55, rue des Bruyères
1274 Howald / LU
[2014/21]
Former [2013/27]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Former [2012/47]Dennemeyer & Associates S.A.
55, rue des Bruyères
1274 Howald / LU
Former [2008/45]Machtalère, Georges, et al
Dennemeyer & Associates S.A. 55, rue des Bruyères
1274 Howald / LU
Former [2007/13]Schmitz, Jean-Marie, et al
Dennemeyer & Associates S.A. P.O. Box 1502
1015 Luxembourg / LU
Application number, filing date05759367.512.07.2005
[2007/13]
WO2005IL00736
Priority number, dateUS20040586697P12.07.2004         Original published format: US 586697 P
[2007/13]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006038208
Date:13.04.2006
Language:EN
[2006/15]
Type: A2 Application without search report 
No.:EP1765378
Date:28.03.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 13.04.2006 takes the place of the publication of the European patent application.
[2007/13]
Type: B1 Patent specification 
No.:EP1765378
Date:16.04.2014
Language:EN
[2014/16]
Search report(s)International search report - published on:US03.05.2007
(Supplementary) European search report - dispatched on:EP01.10.2007
ClassificationIPC:C07K19/00, C07K14/47, C07K16/18, C07K16/30, A61K38/17
[2013/01]
CPC:
A61K38/1709 (EP,US); A61P13/08 (EP); A61P35/00 (EP);
A61P35/04 (EP); A61P9/10 (EP); C07K14/4702 (EP,US);
C07K14/82 (EP,US); C07K16/18 (EP,US); C07K16/30 (EP,US);
C07K19/00 (EP,US); A61K2039/505 (EP,US) (-)
Former IPC [2007/43]A61K39/395, C07K16/30
Former IPC [2007/26]A61K39/395, C07K1/00, C07K14/00, C07K17/00
Former IPC [2007/13]A61K38/17
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/13]
TitleGerman:MITTEL ZUR DOWN-REGULIERUNG EINES MSF-A-ABHÄNGIGEN HIF-1A UND SEINE VERWENDUNG BEI DER BEHANDLUNG VON KREBS[2007/13]
English:AGENT CAPABLE OF DOWNREGULATING AN MSF-A-DEPENDENT HIF-1A AND USE THEREOF IN CANCER TREATMENT[2013/10]
French:AGENTS CAPABLE DE REGULER A LA BAISSE UN HIF-1G(A) DEPENDANT DE MSF-A ET UTILISATION DE CEUX-CI POUR TRAITER UN CANCER[2013/10]
Former [2007/13]AGENT CAPABLE OF DOWNREGULATING AN MSF-A-DEPENDENT HIF-1A ANDUSE THEREOF IN CANCER TREATMENT
Former [2007/13]AGENTS CAPABLE DE REGULER A LA BAISSE UN HIF-1$G(A) DEPENDANT DE MSF-A ET UTILISATION DE CEUX-CI POUR TRAITER UN CANCER
Entry into regional phase11.12.2006National basic fee paid 
11.12.2006Search fee paid 
11.12.2006Designation fee(s) paid 
11.12.2006Examination fee paid 
Examination procedure11.12.2006Amendment by applicant (claims and/or description)
11.12.2006Examination requested  [2007/13]
13.02.2008Despatch of a communication from the examining division (Time limit: M04)
18.06.2008Reply to a communication from the examining division
21.08.2009Despatch of a communication from the examining division (Time limit: M04)
21.12.2009Reply to a communication from the examining division
30.11.2010Despatch of a communication from the examining division (Time limit: M04)
01.04.2011Reply to a communication from the examining division
11.06.2012Despatch of a communication from the examining division (Time limit: M04)
07.08.2012Reply to a communication from the examining division
08.02.2013Communication of intention to grant the patent
18.06.2013Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
11.09.2013Communication of intention to grant the patent
19.12.2013Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
27.01.2014Communication of intention to grant the patent
06.03.2014Fee for grant paid
06.03.2014Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.02.2008
Opposition(s)19.01.2015No opposition filed within time limit [2015/13]
Fees paidRenewal fee
11.12.2006Renewal fee patent year 03
15.07.2008Renewal fee patent year 04
20.07.2009Renewal fee patent year 05
27.07.2010Renewal fee patent year 06
25.07.2011Renewal fee patent year 07
23.07.2012Renewal fee patent year 08
26.07.2013Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.07.2005
AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
TR16.04.2014
IE12.07.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
CH31.07.2014
LI31.07.2014
IS16.08.2014
PT18.08.2014
[2016/33]
Former [2016/32]HU12.07.2005
AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
IE12.07.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
CH31.07.2014
LI31.07.2014
IS16.08.2014
PT18.08.2014
Former [2016/21]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
IE12.07.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
CH31.07.2014
LI31.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/37]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
IE12.07.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
CH31.07.2014
LI31.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/36]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
CH31.07.2014
LI31.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/20]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
CH31.07.2014
LI31.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/18]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/13]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
LU12.07.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/11]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/10]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
SE16.04.2014
SK16.04.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/08]AT16.04.2014
BE16.04.2014
CY16.04.2014
DK16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/02]AT16.04.2014
CY16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2014/51]AT16.04.2014
CY16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
Former [2014/50]CY16.04.2014
ES16.04.2014
FI16.04.2014
LT16.04.2014
LV16.04.2014
NL16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
GR17.07.2014
IS16.08.2014
Former [2014/49]CY16.04.2014
FI16.04.2014
LT16.04.2014
BG16.07.2014
IS16.08.2014
Former [2014/48]CY16.04.2014
LT16.04.2014
BG16.07.2014
Former [2014/47]CY16.04.2014
Documents cited:Search[PA]WO2004074441  (US GOV HEALTH & HUMAN SERV [US], et al) [PA] 1-31 * paragraph [0044] * * claims 9,10,18-21,29,30 *;
 [XA]  - NAGATA K ET AL, "Filament formation of MSF-A, a mammalian septin, in mammary HMEC cells depends on interactions with microtubules.", MOLECULAR BIOLOGY OF THE CELL, & 42ND ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 14-18, 2002, (200211), vol. 13, no. Supplement, ISSN 1059-1524, page 189a, XP009089574 [X] 1-3 * abstract * [A] 4-31
 [XA]  - SURKA M C ET AL, "The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis", MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US, (200210), vol. 13, no. 10, ISSN 1059-1524, pages 3532 - 3545, XP002317660 [X] 1-3 * page 3533, column R, paragraph 3 * * page 3534, column R, paragraph 4 - page 3535, column L, paragraph 1 * * page 3538, column R, paragraph 2 - page 3541, column R, line 2 * * page 3543, column R, paragraph 2 * [A] 4-31

DOI:   http://dx.doi.org/10.1091/mbc.E02-01-0042
 [A]  - RUSSELL S E H ET AL, "Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (20000901), vol. 60, no. 17, ISSN 0008-5472, pages 4729 - 4734, XP002394761 [A] 1-31 * page 4729, column R, lines 27-34 * * page 4731, column R, paragraph 3 * * page 4734, column L, paragraph 2 * * figure 3 *
 [T]  - AMIR SHARON ET AL, "MSF-A interacts with hypoxia-inducible factor-1 alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis", CANCER RESEARCH, (200601), vol. 66, no. 2, ISSN 0008-5472, pages 856 - 866, XP002451233 [T] * page 856 - page 866 *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-05-2738
International search[X]  - LEE ET AL., "Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2003), vol. 300, pages 241 - 246, XP001202149

DOI:   http://dx.doi.org/10.1016/S0006-291X(02)02787-0
 [Y]  - KALIKIN ET AL., "Genomic and Expression anaylsis of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 Region of Loss in Breast cancer and ovarian cancer", GENOMICS, (2000), vol. 63, pages 165 - 172, XP004439437

DOI:   http://dx.doi.org/10.1006/geno.1999.6077
 [Y]  - NAGATA ET AL., "Filament formation of MSF-A, a mammalian septin, in human mammary epithelial cells depends on interaction with microtubules", JOURNAL OF BIOLOGICAL CHEMISTRY, (2003), vol. 278, no. 20, pages 18538 - 18543, XP003012725

DOI:   http://dx.doi.org/10.1074/jbc.M205246200
 [Y]  - SCHINDL ET AL., "Overexpression of Hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer", CLINICAL CANCER RESEARCH, (2002), vol. 8, pages 1831 - 1837, XP003012726
by applicant   - SEMENZA GL., NAT. REV. CANCER, (2003), vol. 3, pages 721 - 732
    - PAUL SA; SIMONS JW; MABJEESH NJ, J. CELL PHYSIOL., (2004), vol. 200, pages 20 - 30
    - QUINTERO M; MACKENZIE N; BRENNAN PA, EUR. J. SURG. ONCOL., (2004), vol. 30, pages 465 - 8
    - LI J ET AL., CANCER RES., (2004), vol. 64, pages 94 - 101
    - CHOI KS ET AL., J. BIOCHEM. MOL. BIOL., (2003), vol. 36, pages 120 - 7
    - ISAACS JS ET AL., J BIOL. CHEM., (2004), vol. 279, pages 16128 - 35
    - ESCUIN D ET AL., CANCER BIOL THER., (2004), vol. 3, no. 7
    - WELSH SJ; POWIS G., CURR CANCER DRUG TARGETS, (2003), vol. 3, no. 6, pages 391 - 405
    - MACPHERSON GR; FIGG WD, CANCER BIOL. THER., (2004), vol. 3, no. 6
    - MIE LEE Y ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2003), vol. 300, pages 241 - 6
    - KUBO T ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2004), vol. 318, no. 4, pages 1006 - 11
    - STUDIER ET AL., METHODS IN ENZYMOL., (1990), vol. 185, pages 60 - 89
    - BRISSON ET AL., NATURE, (1984), vol. 310, pages 511 - 514
    - TAKAMATSU ET AL., EMBO J., (1987), vol. 6, pages 307 - 311
    - CORUZZI ET AL., EMBO J., (1984), vol. 3, pages 1671 - 1680
    - BROGLI ET AL., SCIENCE, (1984), vol. 224, pages 838 - 843
    - GURLEY ET AL., MOL. CELL. BIOL., (1986), vol. 6, pages 559 - 565
    - WEISSBACH; WEISSBACH, Methods for Plant Molecular Biology, ACADEMIC PRESS, (1988), pages 421 - 463
    - MABJEESH, N.J. ET AL., "Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteasome pathway in prostate cancer cells", CANCER RES., (2002), vol. 62, pages 2478 - 2482
    - MABJEESH NJ ET AL., "2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIP", CANCER CELL, (2003), vol. 3, pages 363 - 375
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.